BSG Response to White Paper: 'Healthy Lives, Healthy People'
Responses to Public Health White Paper: 'Healthy Lives, Healthy People: Our Strategy for Public Health in England'
Submitted 31st March 2011
- BSG Response [ 270 kb ]
The organisations that contributed to the joint response are:
- The British Association for the Study of the Liver
- The British Society of Gastroenterology
- The British Liver Trust
- The Hepatitis C Trust
- Alcohol Concern
- Joint Response [ 528 kb ]
Chicago Classification Criteria of Esophageal Motility Disorders (EPT)
Chicago Classification Criteria of Esophageal Motility Disorders Defined in High Resolution Esophageal Pressure Topography (EPT)
High resolution esophageal pressure topography (EPT) is an evolutionary technology incorporating the combination of high resolution manometry (HRM) and pressure topography plotting in the form of Clouse plots introduced in 2000 for the clinical evaluation of esophageal motility. Prior to that, EPT had been developed and utilized as a highly innovative research modality. The HRM Working Group first met in San Diego during DDW 2007 with the objective of adapting EPT to the clinical evaluation of esophageal motility. Since then, a series of HRM Working Group meetings have ensued on a more-or-less annual basis to review, critique, and plan the iterative process of developing a practical classification for esophageal motility disorders based on EPT-specific metrics and criteria. The classification scheme was initially branded 'The Chicago Classification' in 2007 following a series of seminal publications defining key EPT metrics and interpretation criteria optimized for clinical EPT studies emanating from a group of investigators at Northwestern University in Chicago. Since then, two iterations of the Chicago Classification have been published summarizing the incremental development of the classification scheme. The most recent meeting of the HRM Working Group was in Ascona, Switzerland in conjunction an international congress focused on the clinical evaluation of esophageal disease. This paper summarizes the Chicago Classification of esophageal motility disorders emanating from the meeting at the Ascona congress.
- Download document [ 4.4 Mb ]
Specialty Certificate Examination
The Exam: The BSG, in partnership with the Federation of Royal Colleges of Physicians of the UK organises and delivers the Specialty Certificate Examination in Gastroenterology. The first examination was held in 2008. The examination is currently held in April every year.
UK Trainees: The Specialty Certificate Examination (SCE) is a compulsory component of assessment for Certificate of Completion of Training (CCT) for all UK trainees. The examination compliments workplace-based assessments and ensures that trainees have sufficient knowledge to practice safely and competently as consultants.
Outside the UK: The SCE is open to all doctors who are in training or have completed their training from any part of the world. Applicants are no longer required to hold the MRCP (UK). The exam is a computer-based test and is held in several centres throughout the world.
Date of SCE Examination: The next Gastroenterology SCE Examination will take place on 27th April 2017. UK registration period: 29th December 2016 - 23rd March 2017. (European registration period: 29th December 2016 - 26th January 2017).
Dr Mounes Dakkak
Lead Specialist for Gastroenterology SCE
BSG guidance on the use of faecal calprotectin testing in IBD
Updated guidance document on use of faecal calprotectin – both in assessment of GI symptoms, and also in patients with known IBD.
Dr Barney Hawthorne, Chair BSG IBD Section Committee, October 2016.
Differentiation between inflammatory bowel disease (IBD) and functional gut disorders, and the determination of mucosal disease activity in established cases of IBD remain the cornerstones of disease diagnosis and management. Non-invasive, accurate biomarkers of gut inflammation are needed due to the variability of symptoms, the inaccuracies of currently available blood markers and the cost and invasive nature of endoscopy. Numerous biomarkers have been used and/or considered with some in current use...
- Download guidance [ 38 kb ]
NICE guidance on molecular testing strategies for Lynch syndrome in people with colorectal cancer
An estimated 175,000 people have Lynch syndrome in the UK, however 95% of those do not know they have it. NICE recommends that microsatellite instability (MSI) testing or immunohistochemistry (IHC) should be used on all colorectal cancers, when first diagnosed, to detect abnormalities that might mean the presence of Lynch Syndrome. Where these tests show the person has a risk of having Lynch syndrome, the guidance recommends that further tests are carried out to confirm the diagnosis. Because Lynch Syndrome is an inherited condition, a positive test can also lead to testing for family members. While these tests have been available for a while, there is currently wide variation in the provision of testing for Lynch syndrome and other inherited colorectal cancers. Expanding testing to all people with colorectal cancer will increase the detection of Lynch syndrome and identify families who could benefit from genetic testing to determine if other family members have the condition. This could lead to increased surveillance and consequently improved patient outcomes through earlier diagnosis and treatment.
Page 4 of 16